Online follow-up of individuals with gastroesophageal reflux disease using a patient-reported outcomes instrument: results of an observational study

BMC Gastroenterology

Martijn GH van Oijen¹  Merel M Tielemans² 

[1] Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA;Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, PO Box 90153, ‘s-Hertogenbosch, ME 5200, The Netherlands

关键词: GerdQ;    Healthcare visit;    PPI;    GERD;    The internet;   

Others  :  857573
DOI  :  10.1186/1471-230X-13-144

 received in 2013-04-23, accepted in 2013-09-20,  发布年份 2013

【 摘 要 】

Background

Many individuals with gastroesophageal reflux disease (GERD) never visit their general practitioner. Therefore, prospective data about GERD and its natural history in the general population are scarce. The aims of this study were to assess symptoms over time and consultation reasons in an Internet population with GERD.

Methods

Visitors (18–79 years) to a GERD information website who completed the GerdQ self-assessment questionnaire were invited to participate. Follow-up GerdQ questionnaires were sent after 4, 12 and 24 weeks, and those who had a total GerdQ score ≥ 8 and responded to at least the baseline and 4-week questionnaires (within 2–7 weeks) were included in the analyses. Outcome in proton pump inhibitor (PPI) and non-PPI users was classified as symptom improvement, symptom persistence/stable symptoms, or symptom relapse according to GerdQ scores.

Results

A total of 403 non-PPI users (mean age 48 years, 40% male) and 304 PPI users (mean age 51 years, 41% male) were included. After 24 weeks, symptom improvement was present in 66% of non-PPI users (45/68) and 8% of PPI users (6/73), while persisting symptoms were reported by 24% (16/68) and 89% (65/73) respectively (baseline symptoms did not influence outcome at 24 weeks). Fifty-five percent of PPI users (116/210) and 37% of non-PPI users (76/207) who intended to visit a healthcare practitioner, performed one or more healthcare visits in the interim. Most frequently reported reason for consultation was persistence of symptoms.

Conclusions

GERD symptoms were persistent in the majority of PPI users during our 24-week follow-up, while almost two thirds of non-PPI users reported symptom improvement. Online follow-up of an Internet population with GERD is feasible.

【 授权许可】

   
2013 Tielemans and van Oijen; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Dent J, El-Serag HB, Wallander MA, Johansson S: Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005, 54(5):710-717.
• [2]Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted county, Minnesota. Gastroenterology 1997, 112(5):1448-1456.
• [3]Kahrilas PJ: Clinical practice, gastroesophageal reflux disease. N Engl J Med 2008, 359(16):1700-1707.
• [4]Fedorak RN, Veldhuyzen Van Zanten S, Bridges R: Canadian digestive health foundation public impact series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol 2010, 24(7):431-434.
• [5]Gisbert JP, Cooper A, Karagiannis D, Hatlebakk J, Agreus L, Jablonowski H, Nuevo J: Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. Health Qual Life Outcomes 2009, 7:90. BioMed Central Full Text
• [6]Wahlqvist P, Karlsson M, Johnson D, Carlsson J, Bolge SC, Wallander MA: Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol Ther 2008, 27(10):960-970.
• [7]Bruley Des Varannes S, Lofman HG, Karlsson M, Wahlqvist P, Ruth M, Furstnau ML, Despiegel N, Stalhammar NO: Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France. BMC Gastroenterol 2013, 13:39. BioMed Central Full Text
• [8]Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Muller-Lissner SA: Three year follow up of patients with gastrooesophageal reflux disease. Gut 1992, 33(8):1016-1019.
• [9]Vakil N: Disease definition, clinical manifestations, epidemiology and natural history of GERD. Best Pract Res Clin Gastroenterol 2010, 24(6):759-764.
• [10]Hungin AP, Hill C, Raghunath A: Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther 2009, 30(4):331-342.
• [11]Health information online. Pew Internet & American Life Project; 2005. http://www.pewinternet.org/Reports/2005/Health-Information-Online.aspx webcite
• [12]Steinbrook R: Searching for the right search–reaching the medical literature. N Engl J Med 2006, 354(1):4-7.
• [13]Tang H, Ng JH: Googling for a diagnosis–use of google as a diagnostic aid: internet based study. BMJ 2006, 333(7579):1143-1145.
• [14]Powell J, Inglis N, Ronnie J, Large S: The characteristics and motivations of online health information seekers: cross-sectional survey and qualitative interview study. J Med Internet Res 2011, 13(1):e20.
• [15]Jones R, Junghard O, Dent J, Vakil N, Halling K, Wernersson B, Lind T: Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2009, 30(10):1030-1038.
• [16]Jonasson C, Moum B, Bang C, Andersen KR, Hatlebakk JG: Randomised clinical trial: a comparison between a GerdQ-based algorithm and an endoscopy-based approach for the diagnosis and initial treatment of GERD. Aliment Pharmacol Ther 2012, 35(11):1290-1300.
• [17]Jonasson C, Wernersson B, Hoff DA, Hatlebakk JG: Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2013, 37(5):564-572.
• [18]Tielemans MM, Jansen JB, Van Oijen MG: Open access capture of patients with gastroesophageal reflux disease using an online patient-reported outcomes instrument. Interact J Med Res 2012, 1(2):e7.
• [19]Shaw M, Dent J, Beebe T, Junghard O, Wiklund I, Lind T, Johnsson F: The reflux disease questionnaire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes 2008, 6:31. BioMed Central Full Text
• [20]Revicki DA, Wood M, Wiklund I, Crawley J: Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Quality Life Res 1998, 7(1):75-83.
• [21]Jones R, Coyne K, Wiklund I: The gastro-oesophageal reflux disease impact scale: a patient management tool for primary care. Aliment Pharmacol Ther 2007, 25(12):1451-1459.
• [22]El-Serag H, Becher A, Jones R: Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010, 32(6):720-737.
• [23]Malfertheiner P, Nocon M, Vieth M, Stolte M, Jaspersen D, Koelz HR, Labenz J, Leodolter A, Lind T, Richter K, et al.: Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care–the ProGERD study. Aliment Pharmacol Ther 2012, 35(1):154-164.
• [24]Cremonini F, Ziogas DC, Chang HY, Kokkotou E, Kelley JM, Conboy L, Kaptchuk TJ, Lembo AJ: Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010, 32(1):29-42.
• [25]Jones R, Armstrong D, Malfertheiner P, Ducrotte P: Does the treatment of gastroesophageal reflux disease (GERD) meet patients’ needs? A survey-based study. Curr Med Res Opin 2006, 22(4):657-662.
• [26]Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, Brill JV: American gastroenterological association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008, 135(4):1383-1391. 1391 e1381-1385
• [27]Dutch Society for Gastroenterology and Hepatology (NVMDL: Guideline Gastroesophageal Reflux Disease [Richtlijn gastro-oesofageale refluxziekte]. Dutch; 2010. http://www.mdl.nl/uploads/240/823/Richtlijn_GORZ_MDL-format_FINAL.pdf webcite